Published in AIDS Res Ther on May 24, 2006
The association between food insecurity and mortality among HIV-infected individuals on HAART. J Acquir Immune Defic Syndr (2009) 2.31
HIV testing and care in Canadian Aboriginal youth: a community based mixed methods study. BMC Infect Dis (2008) 1.08
HIV Among Indigenous peoples: A Review of the Literature on HIV-Related Behaviour Since the Beginning of the Epidemic. AIDS Behav (2015) 1.05
Characterizing the HIV epidemic in the prairie provinces. Can J Infect Dis Med Microbiol (2012) 0.93
Adoption of the chronic care model to improve HIV care: in a marginalized, largely aboriginal population. Can Fam Physician (2013) 0.80
Rates of initial virological suppression and subsequent virological failure after initiating highly active antiretroviral therapy: the impact of aboriginal ethnicity and injection drug use. Curr HIV Res (2010) 0.79
Comparison of late HIV diagnosis as a marker of care for Aboriginal versus non-Aboriginal people living with HIV in Ontario. Can J Infect Dis Med Microbiol (2012) 0.79
HIV disease progression to CD4 count <200 cells/μL and death in Saskatoon, Saskatchewan. Can J Infect Dis Med Microbiol (2013) 0.78
Improvements in HIV treatment outcomes among indigenous and non-indigenous people who use illicit drugs in a Canadian setting. J Int AIDS Soc (2016) 0.76
Simulation study of confounder-selection strategies. Am J Epidemiol (1993) 12.76
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med (1997) 10.62
The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol (1997) 8.88
Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA (2001) 7.63
Socioeconomic inequalities in health. No easy solution. JAMA (1993) 7.11
Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA (1998) 6.69
Barriers to use of free antiretroviral therapy in injection drug users. JAMA (1998) 6.67
Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS (2003) 5.53
Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS (2002) 5.21
The unequal burden of pain: confronting racial and ethnic disparities in pain. Pain Med (2003) 4.56
Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L. Ann Intern Med (2003) 4.46
Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CMAJ (2003) 4.38
Race or class versus race and class: mortality differentials in the United States. Lancet (1990) 3.89
Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver. CMAJ (2002) 3.70
Interim proposal for a WHO Staging System for HIV infection and Disease. Wkly Epidemiol Rec (1990) 3.32
Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ (2003) 3.19
Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology (2002) 2.99
Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr (2000) 2.94
Anemia and survival in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 2.29
The mental health of Aboriginal peoples: transformations of identity and community. Can J Psychiatry (2000) 2.28
Understanding racial disparities in HIV using data from the veterans aging cohort 3-site study and VA administrative data. Am J Public Health (2003) 2.16
Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS (2001) 1.79
Cigarette smoking, bacterial pneumonia, and other clinical outcomes in HIV-1 infection. Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.79
Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy. J Infect Dis (2003) 1.77
Trends in AIDS incidence and survival among racial/ethnic minority men who have sex with men, United States, 1990-1999. J Acquir Immune Defic Syndr (2002) 1.68
HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med (2003) 1.52
Depressive symptoms decline among persons on HIV protease inhibitors. J Acquir Immune Defic Syndr (2000) 1.42
The future face of coinfection: prevalence and incidence of HIV and hepatitis C virus coinfection among young injection drug users. J Acquir Immune Defic Syndr (2004) 1.36
Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS (2002) 1.33
Current status of nutritional deficiencies in Canadian aboriginal people. Can J Physiol Pharmacol (1995) 1.29
HIV-positive injection drug users who leave the hospital against medical advice: the mitigating role of methadone and social support. J Acquir Immune Defic Syndr (2004) 1.27
Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use. AIDS (2001) 1.22
The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients. Clin Infect Dis (2002) 1.19
Racial and ethnic disparities in health: an emergency medicine perspective. Acad Emerg Med (2003) 1.14
Do sex and race/ethnicity influence CD4 cell response in patients who achieve virologic suppression during antiretroviral therapy? Clin Infect Dis (2003) 1.12
Sexual risk profile of young men in Vancouver, British Columbia, who have sex with men and inject drugs. AIDS Behav (2004) 1.08
Workshop report: The effects of psychological variables on the progression of HIV-1 disease. Brain Behav Immun (2004) 1.07
Accessing medication information by ethnic minorities: barriers and possible solutions. Pharm World Sci (2003) 1.06
Cigarette smoking, mental health and social support: data from a northwestern First Nation. Can J Public Health (2004) 1.04
Ethnic and racial differences in long-term survival from hospitalization for HIV infection. J Health Care Poor Underserved (2000) 0.98
Quantifying the effect of health status on health care utilization using a preference-based health measure. Soc Sci Med (2005) 0.97
Low effectiveness of highly active antiretroviral therapy and high mortality in the Greenland HIV-infected population. Scand J Infect Dis (2004) 0.95
Responding to racial and ethnic disparities in use of HIV drugs: analysis of state policies. Public Health Rep (2002) 0.93
HIV-associated risk factors among young Canadian Aboriginal and non-Aboriginal men who have sex with men. Int J STD AIDS (1999) 0.93
Hepatitis C seroprevalence and risk behaviors in patients attending sexually transmitted disease clinics. Sex Transm Dis (2003) 0.89
HIV risk behaviors become survival techniques for aboriginal women. West J Nurs Res (1997) 0.85
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet (2010) 12.82
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 7.49
The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet (2006) 7.17
Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ (2009) 6.03
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med (2003) 5.79
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56
Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS (2002) 5.21
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet (2006) 5.00
Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med (2002) 4.77
Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study. Lancet (2008) 4.70
Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med (2011) 4.68
Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis (2004) 4.55
The financial cost of doctors emigrating from sub-Saharan Africa: human capital analysis. BMJ (2011) 4.54
Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L. Ann Intern Med (2003) 4.46
Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CMAJ (2003) 4.38
Social and structural violence and power relations in mitigating HIV risk of drug-using women in survival sex work. Soc Sci Med (2007) 4.14
"Having the right chemistry": a qualitative study of mentoring in academic medicine. Acad Med (2003) 3.93
Structural and environmental barriers to condom use negotiation with clients among female sex workers: implications for HIV-prevention strategies and policy. Am J Public Health (2009) 3.85
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 3.74
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr (2009) 3.67
Reproductive intentions and outcomes among women on antiretroviral therapy in rural Uganda: a prospective cohort study. PLoS One (2009) 3.66
Changes in Canadian heroin supply coinciding with the Australian heroin shortage. Addiction (2006) 3.65
Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study. Harm Reduct J (2006) 3.49
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis (2008) 3.38
Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr (2006) 3.38
Ureteroenteric anastomotic strictures after radical cystectomy-does operative approach matter? J Urol (2012) 3.30
Training on the internal medicine teaching wards. CMAJ (2003) 3.28
Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. Alcohol Clin Exp Res (2004) 3.24
Rationale for evaluating North America's first medically supervised safer-injecting facility. Lancet Infect Dis (2004) 3.20
Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ (2003) 3.19
Absence of the SRC-2 coactivator results in a glycogenopathy resembling Von Gierke's disease. Science (2008) 3.17
Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. Lancet (2011) 3.14
Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis (2010) 3.12
The Canadian government's treatment of scientific process and evidence: inside the evaluation of North America's first supervised injecting facility. Int J Drug Policy (2008) 3.05
Estimated numbers of men and women infected with HIV/AIDS in Tijuana, Mexico. J Urban Health (2006) 3.04
Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS (2007) 3.04
Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology (2002) 2.99
Food insecurity is associated with incomplete HIV RNA suppression among homeless and marginally housed HIV-infected individuals in San Francisco. J Gen Intern Med (2008) 2.97
Does ratification of human-rights treaties have effects on population health? Lancet (2009) 2.93
Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog (2007) 2.81
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA (2008) 2.77
Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme. AIDS (2002) 2.74
Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr (2005) 2.74
Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction (2010) 2.65
Displacement of Canada's largest public illicit drug market in response to a police crackdown. CMAJ (2004) 2.63
Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. CMAJ (2004) 2.62
A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis (2006) 2.61
Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin Infect Dis (2005) 2.58
Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis (2011) 2.55
Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs. CMAJ (2009) 2.51
Improving the recruitment activity of clinicians in randomised controlled trials: a systematic review. BMJ Open (2012) 2.50
When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients. Lancet Infect Dis (2005) 2.48
Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis (2005) 2.42
The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS (2007) 2.39
The impact of a police presence on access to needle exchange programs. J Acquir Immune Defic Syndr (2003) 2.37
Alterations in xenobiotic metabolism in the long-lived Little mice. Aging Cell (2007) 2.35
Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend (2006) 2.33
CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 2.32
The association between food insecurity and mortality among HIV-infected individuals on HAART. J Acquir Immune Defic Syndr (2009) 2.31